openPR Logo
Press release

North America and Europe PEGylated Drugs Market 2018 – 2024 | Merck, Shire Group, Amgen, UCB, AstraZeneca, Sigma Tau, Pfizer, Roche, and Biogen

08-22-2018 09:34 AM CET | Health & Medicine

Press release from: Global Market Insights, Inc.

North America and Europe PEGylated Drugs Market 2018 – 2024 |

Owing to the advent of advanced medical therapies and innovative technologies, North America and Europe PEGylated drugs market has witnessed remarkable transformation in the recent years. The massive proliferation of tech breakthroughs in the healthcare and medical devices industry has intensified the competitive landscape of this business space. Numerous firms partaking in North America and Europe PEGylated drugs market have been striving to bring forth a range of high-grade products to effectively treat chronic diseases such as cancer and multiple sclerosis. Consequentially, the unveiling of these progressive medicines and their mainstream utilization across healthcare sector would have an optimistic influence on North America and Europe PEGylated drugs industry in the forthcoming years.

A brief overview of how technological advancements would impel North America and Europe PEGylated drugs industry trends

Citing an instance to affirm the significance of the ongoing innovations across North America and Europe PEGylated drugs industry, the European Commission approved the biopharmaceutical giant Shire’s second line combination therapy, Onivyde, in 2016. Apparently, this has made Onivyde, which basically is a pegylated liposomal irinotecan hydrochloride trihydrate, the first licensed treatment therapy that can be administered to adults with metastatic adenocarcinoma of pancreas. Reportedly, the latest EU license approval follows the U.S. Food and Drug Administration’s (FDA) sanction of the drug, after Shire secured U.S. marketing authorization in October 2015.

Get a Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/2511

Speaking in the similar context, it would be prudent to mention that pancreatic cancer is the seventh leading cause of death across the world and fourth in Europe. For the record, pancreatic cancer causes approximately 330,400 deaths annually throughout the continent, as per reliable estimates. Moreover, poor prognosis and delayed medical intervention has further aggravated the current medical care scenario. However, the prevailing cancer treatment procedures would undergo a revolution of sorts with the arrival of advanced drugs such as Onivyde, which would eventually impact North America and Europe PEGylated drugs market outlook, cite analysts. For the record, cancer application held 60% of the overall North America and Europe PEGylated drugs industry share in 2017.

Concurrently, it has been observed that a number of prominent firms are focusing on development and commercialization of targeted therapies to treat rare illnesses. For instance, one of the notable participants in North America and Europe PEGylated drugs industry, Eiger BioPharmaceuticals, Inc recently announced to have received orphan designation by U.S. FDA for its pegylated interferon lambda 1a. The Orphan Drug Designation Program provides orphan status to biologics and drugs which have been defined as safe for diagnosing, treating or preventing rare illnesses that affect less than 200,000 residents of the U.S.

As has been reported, the latest drug by Eiger is being termed as an effective potential treatment for chronic hepatitis delta virus (HDV) infection. Moreover, Lambda is said to be a first in class, well-characterized, late stage, type III interferon that stimulates immune responses which are considered critical for generating host protection from viral infections.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/2511

For the record, hepatitis delta is considered as one of the most severe forms of viral hepatitis in humans and is caused by infection with HDV. With a significant impact on global health, hepatitis delta, as per reliable estimates, affects about 15-20 million people worldwide. Therefore, the launch of Eiger’s Lambda is anticipated to predominantly assist healthcare providers in lowering the mortality rates caused by hepatitis delta. This would eventually propel the commercialization potential of North America and Europe PEGylated drugs market over the ensuing years from hepatitis treatment application. The segment accounted for a revenue of USD 156 million in 2017.

With the swift advances being made in developing antibody drug conjugates, immunotherapies, cell therapies, and gene therapies, North America and Europe PEGylated drugs industry is projected to tread along a lucrative growth path. In addition to this, the rising acceptance of biologics drugs, including interferons, colony stimulating factors, and monoclonal antibodies, to treat chronic diseases would further boost the overall growth potential of this business space. In fact, as per a research report compiled by Global Market Insights, Inc., North America and Europe PEGylated drugs market share is estimated to surpass USD 10.5 billion by 2024.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release North America and Europe PEGylated Drugs Market 2018 – 2024 | Merck, Shire Group, Amgen, UCB, AstraZeneca, Sigma Tau, Pfizer, Roche, and Biogen here

News-ID: 1193093 • Views: 221

More Releases from Global Market Insights, Inc.

Hypochlorite Bleaches Market to hit US$ 300 Mn 2025 | Top Key Players like Adity …
As per the research report by Global Market Insights, Inc., Global Hypochlorite Bleaches Market to cross USD 300 million by 2025 and grow at 3.4% CAGR from 2019 to 2025. It has been projected that the Global hypochlorite bleaches market is expected to reach a consumption of around 485-kilo tons by 2025. Water scarcity as well as rising water costs have led to more emphasis being laid on water recycling and
Feminine Hygiene Products Market: Growing awareness regarding intimate health in …
Global Market Insights, Inc., announces an ongoing comprehensive report on the Feminine Hygiene Products Market. One of the most hushed topics across the world is female hygiene, the negligence of which results in several diseases. Studies claim that nearly 30% to 60 % women across the globe develop urinary tract infection once in their lifetime, mainly due to negligence in proper intimate hygiene. Dearth of knowledge regarding the negative consequences of
Examination Gowns Market 2020 business trends & growth opportunities to 2026
Global Market Insights, Inc., announces an ongoing comprehensive report on the Examination Gowns Market. The exposure to various kinds of hospital acquired infections has led to a spate of health problems for the healthcare professionals as well has the patients. In this regard, experts have been massively shifting to adoption of personal protective equipment or clothing, examination gowns, protecting them from all kinds of infections. These gowns are present in the
Nonwoven Packaging Market to witness increased demand from pharmaceutical sector …
Global Market Insights, Inc., announces an ongoing comprehensive report on the Nonwoven Packaging Market. With the world struggling to fight against negative consequences of industrialization and increased carbon emissions, nonwovens or nonwoven fabrics have emerged as an intrinsic solution for all ecological imbalances across the globe. These fabrics are made from staple fiber and long fibers, merged together by chemical, heat, or mechanical treatment. These are generally used in textile manufacturing

All 5 Releases


More Releases for Europe

Synthetic Biology Market – Europe
Synthetic Biology Market Europe is expected to reach USD XX Billion by 2026 from USD XX Billion in 2016 at a CAGR of XX% (Detailed analysis of the market CAGR is provided in the report). Synthetic biology has expanded into various interdisciplinary fields that may be defined as the combination of artificial design and engineering to produce biological systems, chemicals or living organisms. Synthetic biology is also used for improving applications
Europe Wooden Doors Market
Europe Wooden Doors Market https://www.qandqmarketresearch.com/reports/wooden-doors-market-78 This report studies the Wooden Doorsmarket status and outlook of Europe and major countries, from angles of players, countries, product types and end industries; this report analyzes the top players in Europe and major countries, and splits the Wooden Doors market by product type and applications/end industries. The global Wooden Doors market is valued at XX million USD in 2018 and is expected to reach XX million
Europe Radiotherapy Market
The Europe Radiotherapy Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Europe Radiotherapy Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based
Europe Business Assembly
The Europe Business Assembly (EBA) is an international corporation for the evolution and implementation of economic and social development. The company was established in April 2000 and its history shows a plethora of promising initiatives, creative growth and professional victories. EBA’s activity demonstrates the capabilities and power of professional partnership. The year 2000 saw the beginning and the foundation of EBA with the signing of the memorandum of cooperation and
Smartsourcing in Eastern Europe
In 2008 the outsourcing business of Eastern Europe was estimated at nearly $2 billion, representing just a tiny fraction of the global IT outsourcing market, estimated at about $386 billion. According to the Gartner Dataquest predictions, in the next four years Eastern Europe is expected to outstrip the rest of the offshore market concentrated mainly in the “classical” locations like India. By 2010 Eastern Europe’s IT outsourcing market share is
Home Control conquers Europe
European Home Control Summit attracts participation from leading International companies and organizations 29. February 2008 - Copenhagen/Frankfurt - The first European Wireless Home Control Summit on 9 April 2008, taking place parallel to Light + Building, features leading companies such as Merten, Horstmann, Danfoss, and market researcher Parks Associates as well as publicly funded organizations like the Danish Energy Saving Trust (DEST) presenting the newest trends, products and market strategies pertaining